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Abstract  
Anticancer drugs as inhibitors of vascular smooth muscle cells (VSMCs) proliferation are 
commonly used in clinical treatment. This study aims to investigate how elemene affects the 
proliferation of VSMCs, the restenosis, and the reendothelialization after implantating the elemene-
coated stents. VSMCs derived from rat aortic were tested the cell proliferation, cell cycle, migration, 
apoptosis, cytoskeletal protein F-action, intracellular Ca2+, IncRNA chip and gene expression of 
PCNA, P53, Cx43 when cultured with elemene. It was found that elemene can inhibit proliferation, 
induce apoptosis and block the connections between VSMCs in a dose-dependent manner. IncRNA 
chip analysis has revealed that there was a significant difference in the expression of 1417 genes 
and 34 signaling pathways. Elemene liposome membranes prepared by electrostatic spray could 
also inhibit the proliferation of VSMCs. In addition, after implanting the elemene-coated stent into 
rabbit iliac artery for 12 weeks, the surface of elemene-coated stents was fully covered with a layer 
of neointima and a few platelets. However, a large number of platelets aggregated and attached on 
the uncoated stents (control samples). In conclusion, Elemene could inhibit VSMCs proliferation in 
vitro which involved in the regulation of various signal transduction pathways and elemene-coated 
stents could promote endothelialization after stent implantation. Thus elemene has great potential 
for the clinical treatment of restenosis and reendothelialization. 
 
 
 
Introduction  
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The development of drug-eluting stents (DES) has made s step change in reducing rates of restenosis 
after percutaneous coronary intervention. However, the rapid implementation of DES in different 
patients and complex lesions can introduce in-stent restenosis (ISR) 1, 2, which is problematic. ISR 
is a complicated process which contains many pathological changes, including intimal injury, 
thrombus formation, migration and proliferation of VSMCs and vascular remodeling. The abnormal 
proliferation and phenotypic change of VSMCs is one of the most important pathogenic mechanisms 
of neointimal hyperplasia and ISR 3. After stent implantation, the intimal was damaged and a number 
of cytokines and growth factors were synthesized and secreted. The local mechanical environment 
of cells also changed, which would affect the intracellular signalling that controls VSMCs’s 
migration, proliferation and secretion of extracellular matrix, and cell phenotype. This consequently 
leads to the formation of neointimal hyperplasia and ISR 4-7. The occurrence and molecular 
biological mechanism of VSMCs proliferation and endothelial regeneration after vascular injury are 
similar to cancer development with enhanced cell proliferation and reduced apoptosis 8. As 
inhibitors of VSMCs proliferation, anticancer drugs are commonly used in clinical treatment 9, 10.  
Elemene (1-methyl-1-vinyl-2, 4-diisopropenyl-cyclohexane) is an effective antitumor drug 
which can reduce tumor cells’ mitosis, induce tumor cell apoptosis, block tumor cells into the G2/M 
phase from the S phase, inhibit tumor angiogenesis and so on 11. Elemene at low concentration can 
inhibit neointimal hyperplasia in the rat carotid artery after balloon injury while protecting vascular 
endothelial cell from injury, therefore, it promotes vascular endothelial cells proliferation 12. It is 
suggested that elemene has potential for treating atherosclerosis and restenosis 13. Elemene also has 
the potential for inhibiting thrombus formation 13, angiogenesis 14, VSMCs proliferation and 
migration as well as intimal hyperplasia 12. In addition, it also protects VSMCs against oxidative 
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injuries 15 and inflammation 16. The study aims to investigate the influence of elemene on VSMCs 
proliferation and gene expression under both static and cyclic stretch. Intimal hyperplasia, 
thrombosis, and reendothelialization are investigated after elemene-coated stents implant into the 
rabbit iliac artery. It is anticipated that this study could pave the way for adopting elemene for 
cardiovascular interventions.  
 
Materials and methods  
Animals and materials 
Fifteen inbred strain New Zealand White male rabbits (2.6 to 3.5 kg) and ten male Sprague-Dawley 
rats were purchased from the Experimental Animal Center of Third Military Medical University, 
Chongqing, China. After 1 week of normal feeding in the standard environment, the rabbits were 
randomly divided into two groups, i.e., implanted elemene-coated (n=11) and bare (n=9) stents 
group. All rabbits were fed normally pre- and post-stent implantation without feeding any medicine. 
The experimental protocol was in accordance with the “Principles of Laboratory Animal Care” 
(formulated by the National Society for Medical Research) and the “Guide for the Care and Use of 
Laboratory Animals” published by the US National Institutes of Health (NIH Publication No. 85-
23, revised 1996). Ethics approval was granted by the Third Military Medical University ethics 
review board. 
Twenty-five 316L stainless steel stents (1.4 mm × 17 mm), which could be expanded to 3 mm 
were purchased from MeiZhongShuangHe Medical Device Inc., Beijing, China. PLGA polymer 
was obtained from Sigma Inc. (St. Louis, MO, USA). The antibody was dissolved in a sodium 
phosphate buffer (0.15 m/L NaCl and 0.001% Tween-80, pH 7.2) at a concentration of 2.0 mg/mL. 
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Elemene was donated by Dalian Jin-gang Pharmaceutical Co. (5 mg/mL, Dalian, China). 
Cell isolation and culture 
VSMCs were derived from rat aorta following the same protocol as previously described 17. The 
cells were cultured in DMEM/F12 (Hyclone, Beijing, China) and FBS (Hyclone, Beijing, China) 
with P/S. Then immunofluorescence staining of α-SMA (Boster, Wuhan, China) was used to ensure 
good imaging quality of VSMCs. VSMCs between passages 3 to 8 are used in all experiments. 
Proliferation, cyclic and apoptosis analysis 
VSMCs at a density of 1×105/mL were cultured for 24 h and were then exposed to elemene at 
various concentrations (6.25 μg/mL, 12.5 μg/mL, 25 μg/mL, 50 μg/mL and 100 μg/mL) and 
elemene liposome membranes with varied elemene surface concentrations (5 μg/mm2, 10 μg/mm2, 
15μg/mm2) for four different time intervals (24 h, 48 h, 72 h and 96 h). The proliferation of cells 
was measured by cell counting and recorded by both stereo microscope and fluorescence 
microscopy. Cell cycle and apoptosis were analyzed by PI staining flow cytometry and Annexin V- 
FITC/PI (Beyotime, Shanghai, China) double staining flow cytometry. 
Migration of VSMCs  
The migration of VSMCs was measured using the scratch wound healing assay 18. The VSMCs 
were treated with different concentrations (6.25 μg/mL, 12.5 μg/mL, 25 μg/mL, 50 μg/mL and 100 
μg/mL) of elemene for 24 h. The cell migration pictures were collected at 0 h, 24 h, 48 h and 72 h 
under phase contrast microscope. The commercial image processing software (IMAGE-PRO PLUS) 
was used to measure cell migration distance.  
Another method to detect cell migration was to use the transwell migration assay as previously 
described 19. VSMCs (5×104 cells/chamber) were seeded into the upper chamber (Boyden). Each 
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well was separated into two chambers by a membrane with 8 μm pores. Chemotaxis was achieved 
in the presence of 100% FBS in the bottom chamber. After 8 h, the transwell chambers were rinsed 
in PBS, and the cells at the bottom of the transwell membrane were fixed with 4% 
paraformaldehyde (Boster, Wuhan, China) at 37 °C for 15 min, and then rinsed with PBS. The 
migrated cells were counted manually using a phase contrast microscope. The migration was 
quantified by the analysis of at least 10 random fields per filter. 
Immunofluorescence of intracellular F-action and Ca2+ 
After treating with elemene (25 μg/mL) for 24 h, VSMCs were fixed in 4% paraformaldehyde and 
then incubated with 0.1% Triton X-100 for 10 min, blocked with 1% BSA (Boster, Wuhan, China) 
for 30 min. The F-actin was directly stained with FITC-Phalloidin (1:200 dilution in 1% BSA) 
(Sigma, CA, USA) for 1 h, and the cell nuclei were counterstained with DAPI (Boster Institute of 
Biotechnology, Wuhan, China) for 5 min. The unbound molecules were washed away and the cells 
were assessed using a fluorescence microscope (Olympus BX81, Japan). 
Cyclic strain 
For cyclic strain studies, VSMCs were seeded into fibronectin-coated 6-well Bioflex plates 
(Flexcell International Corp, Burlington, NC). When cells have reached 80% confluence they were 
treated with 100 μg/mL elemene for 2 h. Then the culture medium without serum was added, and a 
Flexercell Tension Plus FX-4000T system was used to apply a physiological level of cyclic strain 
(5% strain, 1 Hz) for 12 h. After being subjected to strain, the VSMCs were harvested for IncRNA 
chips and western blotting assay.  
IncRNA chips and Western Blotting 
The total mRNA was extracted, and cDNA was produced via reverse transcription. The Cy3 
7 
 
fluorescence dye was used for marking the cDNA probe. Hybrid scan and analysis with the 
expression arrays were carried out by IncRNA chip (KangChen Bio-tech, China).  
Cells were dissolved in lysis buffer containing 0.5% protease inhibitor mixture and kept at 37 °C 
for 30 min. The protein concentration of the lysate was determined with a Protein Assay Kit. Protein 
was fixed with loading buffer and kept at -20°C. The entire protein samples from a total cell lysate 
were separated by SDS-PAGE, transferred to immobilon membranes, and incubated with anti-rat 
antibody. After washing and incubation with horseradish peroxidase-linked anti-rabbit IgG, 
immunoreactive proteins were visualized with an ECL Plus detection system and a Versa Doc ND-
2000 molecular imager system. 
Elemene liposome and its characterization 
Elemene, lecithin, and cholesterol were mixed with the ratio of 1:8:2, and completely dissolved by 
adding anhydrous ethanol to form an oil phase. 10 mL phosphate buffer containing 0.05% PEG - 
2000 was placed into a three-necked bottle. The oil phase was then injected into the water phase at 
a slow constant speed by using a syringe needle, in a 50 °C water bath with 30 rpm. After 2 hours, 
ethanol was removed and the mixture was filtrated with 0.22 μm microporous membrane to extract 
the elemene liposomes. The particle size and zeta potential of the elemene liposomes were measured 
by dynamic laser light scattering (Malvern Zetasizer Nano ZS90, Malvern Instruments Ltd, UK). 
Elemene liposome membranes and elemene coated stents by electrostatic spray 
Elemene liposomes were then used as the inner liquid of electronic injection, while PLGA (10 
mg/mL) was the outer solution. Different elemene liposome membranes (5 μg/mm2, 10 μg/mm2, 
15 μg/mm2) were prepared by adjusting the electrostatic spray parameters, such as voltage, current 
velocity, spray distance, and spray time. With 316L stainless steel vascular stent as a receiver, 
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elemene coated stents were then obtained (Supplementary Figure S1). Elemene liposomes coating 
on the stent surface was analysed by scanning electron microscope and stereomicroscope.  
The release rate of elemene liposomes membranes by HPLC 
The PLGA was used as binder matrix for elemene liposome membranes (ELM) and the elemene 
injection membranes (EIM). Both membranes (i.e. PLGA/ELM mixture and PLGA/EIM) were 
placed in 1 mL PBS solution at the temperature of 37 °C wet box with 60 rpm. The membranes 
were retrieved from the solution at various time interval (20 min-28days). The retrieved membranes 
were soaked in 1 mL ethanol 2 h to dissolve residual elemene, followed by oscillating 
demulsification and membrane filtration. They were then injected into liquid chromatography 
special bottle and sealed at 4 °C. Residual elemene was measured by HPLC, which enables us to 
analyse elemene drug release rate. 
In vivo implantation procedures 
The rabbits were anesthetized with pentobarbital sodium (50 mg/mL, 30 mg/kg) through the ear 
vein. The stents mounted on a balloon catheter were implanted into the iliac artery from the left 
carotid artery through a 5F sheath introducer (Terumo, Japan) under fluoroscopy using a guide wire 
(Cook, USA). The stent deployment conditions are less than 1.2:1 (stent: artery) ratio by 
quantitative coronary angiography (QCA). The balloon was inflated at a pressure of 10 atm for 30 
s, deflated, and then slowly withdrawn, leaving the stent in place. QCA was performed before 
implantation and explantation to determine the diameter of the vessel lumen. Fifteen milliliters of 
heparin (250 mL 0.9% NaCl + 6000 U) were administered during the entire angiography. One bare 
stent or elemene-coated stent was implanted into a single iliac artery and was kept in place for 12 
weeks. The animals received no anticoagulant or antiplatelet therapy post operation.  
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Electron microscope 
After 12 weeks, the stent implanted arterial segments were removed and washed in heparin solution 
(1000 mL 0.9% NaCl + 6000 U) and PBS, prior to sectioning. The specimens were post-fixed in a 
2.5% isotonic buffered glutaraldehyde and coated with gold. After that, these samples were 
examined by scanning electron microscope (Model 1000 B, Amray, Bedford, MA, USA).   
Statistical analysis 
The statistical analysis was done by one-way or two-way ANOVA using SPSS. The differences 
among the experimental groups were considered statistically significant when p<0.05. Unless 
indicated, the values were expressed as mean ± SD. 
 
Results  
Elemene inhibits the proliferation of VSMCs and induces apoptosis 
With the increase of elemene concentration, the density of VSMCs decreased gradually and the 
connections between cells were broken and inhibited (Figure 1A, B, C). When the concentration 
was over 12.5 μg/mL (p < 0.05), the synapses increased and the spreading area was significantly 
inhibited. When the concentration reached 100 μg/mL, the number of VSMCs did not increase at 
all. One possible mechanism for this was the increase in cell apoptosis. With the increase of elemene 
concentration, the cell apoptosis rate increased gradually. The apoptosis rate for the group treated 
by 25 μg/mL elemene was twice as the untreated control group (Figure 1D). On the other hand, flow 
cytometry indicated that elemene could keep VSMCs in the stages of S and G2 and thus inhibit the 
proliferation After 25 μg/mL elemene treatment for 24 h, cells in G1 phase, S phase and G2 phase 
were 74.92%, 19.97%, and 5.11%, respectively. Whilst, in untreated control group, the 
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corresponding relative cell populations were 83.45%, 12.80%, and 3.74%, respectively. (Figure 1E). 
The Ca2+/calmodulin could be used to adjust the gap junction for intercellular communication, 
which will then affect cell proliferation, apoptosis, and differentiation. The level of [Ca2+] in 
quiescent cells was stable. However, after the addition of 25 μg/mL elemene, the level of [Ca2+] in 
the cells began to rise in 10 seconds and to reach the peak for about 20 seconds, and its peak value 
is nearly as twice as the quiescent state. Then in the following 10 seconds, it drops to that for 
quiescent cells and goes down by 17% slowly (Figure 1F). 
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Figure 1. Effect of elemene on VSMCs proliferation, cell cycle and apoptosis.  
(A) Phase contrast microscopic images of VSMCs (100×) cultured with β-elemene for 48 h at 
different concentrations. The red arrow indicates the connection between the vascular smooth 
muscle cells was interrupted. Blue arrow indicates the cell synapse was increase. (B, C) The VSMCs 
numbers cultured with elemene for 24 h, 48 h, 72 h, 96 h at the different concentrations. The data 
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are expressed as mean ± SD from 5 separate samples. (*P<0.05 vs. no elemene treated). (D) The 
apoptosis of VSMCs after treatment with elemene at different concentration. With the increase of 
elemene concentration, the cell apoptosis rate increase gradually. The apoptosis rate of the group 
treated by 25 μg/mL elemene is double compared with the control. (E) Cell cycle of VSMCs after 
incubated in DMEM/F12 with 20 %FBS for 24 h with elemene at different concentration. Elemene 
can inhibit the proliferation of VSMCs in the stages of S and G2 by flow cytometry, the percentage 
of the VSMCs is increased by 8.54% compared with the untreated group. (F) Ca2+ in VSMCs 
cultured with 25 μg/mL β-elemene for 24 h. The level of intracellular [Ca2+] rise up considerably 
after 20 seconds, and the rate of increase is twice as high as the quiescent state at 50 seconds. Then 
it declines by 17% about 80 seconds later. 
 
Elemene inhibits the migration of VSMCs 
Another key mechanism of neointima hyperplasia was the migration of VSMCs. Scratch wound 
healing assay revealed that elemene significantly reduced the migration of VSMCs in a dose-
dependent manner (Figure 2A, B). The migrated VSMCs was measured by transwell migration 
assay. In demonstrated that elemene significantly inhibited the migration of VSMCs at centrations 
of 12.5 μg/mL, 25 μg/mL, 50 μg/ mL (p<0.05) and 100 μg/mL (p<0.01) compared with the untreated 
control (Figure 2C). 
At a concentration of 25 μg/mL, elemene significantly affected the number and morphology of 
VSMCs after co-culture with VSMCs for 24 h. Cytoskeleton filaments of the elemene treated group 
were thicker than the control group and cell morphology was elongated (Figure 2D). 
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Figure 2. Migration of VSMCs after co-cultured with elemene.  
(A) The migration distance decrease with the increase of elemene concentration, after co-cultured 
for 72 h. (B) The migration distance have significant differences when the concentration greater 
than 12.5 μg/mL. (*, p < 0.05; **, p < 0.01) (C) Elemene can also inhibit the number of VSMCs 
induced by 100% FBS migrate from upper chamber to the lower one through the transwell 
membrane filter. (D) F-actin in VSMCs cultured with 25 μg/mL elemene for 24 h (×100 and ×200). 
The cells treated with elemene are arranged in a disorder and sparsely way, with narrowed shape 
and decreased spreading area compared with controls. Cytoskeleton filaments of the elemene treated 
group are thicker than the control group.  
 
Effects of elemene on VSMCs under cyclic strain 
Pathological cyclic strain can enable VSMCs to transfer from contractile phenotype to synthetic 
phenotype. In the selected 4 × 44k gene expression profiles, 1417 gene expressions show differences 
(over twice).  Among which, the expression of 699 genes go up and 718 genes decrease. Among 
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these 1417 gene expressions, 34 signaling pathways were involved, including PPAR, MAPK, AKT 
and ERK1/2 (Table 1, Table 2). So we investigated the PCNA, P53, Cx43 expression. It seems that 
elemene affected gene expression in similar way whether under static culture or cyclic strain. Under 
cyclic strain, elemene gave rise to the expression of P53 and inhibited that of PCNA and Cx43 
(Figure 3).  
 
Figure 3. Effects of elemene on VSMCs under cyclic strain.  
(A) IncRNA chip scan of VSMCs and VSMCs which co-cultured with 100 μg/mL elemene for 2 h 
stretching for 12 h. (B) Representative immunoblots of PCNA, P53, Cx43 and GADPH expression 
in VSMCs with different concentrations of elemene to stimulate for 12 h. The quantitative analysis 
of (C) PCNA/GADPH, (D) P53/GADPH, (E) Cx43/GADPH in VSMCs stretching for 12 h after 
treated with different concentration of elemene for 2 h (n=3) . Under the static and cyclic stretches, 
elemene can rise the expression of P53 and inhibit that of PCNA and Cx43. 
 
Table.1 Pathway analysis up differentially expressed gene list 
Pathway 
ID 
Definition Genes 
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rno05213 Endometrial cancer - 
Rattus norvegicus (rat) 
AKT1//AKT2//APC2//AXIN2//CTNNB1//MAPK1 
rno03440 Homologous 
recombination - Rattus 
norvegicus (rat) 
MRE11A//POLD1//RAD52//RPA1 
rno05142 Chagas disease 
(American 
trypanosomiasis) - 
Rattus norvegicus (rat) 
AKT1//AKT2//FAS//GNA15//GNAI1//IKBKG//MAP
K1//TLR4 
rno05160 Hepatitis C - Rattus 
norvegicus (rat) 
AKT1//AKT2//CD81//CLDN22//EIF2AK4//IKBKG//
MAPK1//SCARB1//SOCS3 
rno04012 ErbB signaling pathway 
- Rattus norvegicus (rat) 
ABL2//AKT1//AKT2//AREG//MAPK1//PAK3//TGFA 
rno05145 Toxoplasmosis - Rattus 
norvegicus (rat) 
AKT1//AKT2//GNAI1//IKBKG//MAPK1//PLA2G4B//
RT1-HA//TLR4//XIAP 
rno05212 Pancreatic cancer - 
Rattus norvegicus (rat) 
AKT1//AKT2//ARHGEF6//IKBKG//MAPK1//TGFA 
rno05210 Colorectal cancer - 
Rattus norvegicus (rat) 
AKT1//AKT2//APC2//AXIN2//CTNNB1//MAPK1 
rno05223 Non-small cell lung 
cancer - Rattus 
norvegicus (rat) 
AKT1//AKT2//MAPK1//RASSF5//TGFA 
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rno04120 Ubiquitin mediated 
proteolysis - Rattus 
norvegicus (rat) 
BRCA1//FBXO4//HERC3//KLHL9//PPIL2//RHOBTB
2//SOCS3//XIAP 
rno00232 Caffeine metabolism - 
Rattus norvegicus (rat) 
CYP2A2//NAT2 
rno05215 Prostate cancer - Rattus 
norvegicus (rat) 
AKT1//AKT2//CTNNB1//IKBKG//MAPK1//TGFA 
rno05140 Leishmaniasis - Rattus 
norvegicus (rat) 
FCGR2A//MAPK1//PTGS2//RT1-HA//TLR4 
rno04920 Adipocytokine 
signaling pathway - 
Rattus norvegicus (rat) 
AKT1//AKT2//CPT1A//IKBKG//SOCS3 
rno05211 Renal cell carcinoma - 
Rattus norvegicus (rat) 
AKT1//AKT2//MAPK1//PAK3//TGFA 
rno00071 Fatty acid metabolism - 
Rattus norvegicus (rat) 
ACADSB//CPT1A//CYP4A8//EHHADH 
rno04380 Osteoclast 
differentiation - Rattus 
norvegicus (rat) 
AKT1//AKT2//FCGR2A//IKBKG//MAPK1//SOCS3//
TNFRSF11B 
rno05200 Pathways in cancer - 
Rattus norvegicus (rat) 
AKT1//AKT2//APC2//AXIN2//CTNNB1//FAS//IKBK
G//KITLG//MAPK1//PTGS2//RASSF5//TGFA//WNT
4//XIAP 
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rno04062 Chemokine signaling 
pathway - Rattus 
norvegicus (rat) 
AKT1//AKT2//CCL2//CCL7//GNAI1//GNGT2//IKBK
G//IL8RB//MAPK1 
rno04370 VEGF signaling 
pathway - Rattus 
norvegicus (rat) 
AKT1//AKT2//MAPK1//PLA2G4B//PTGS2 
rno04662 B cell receptor 
signaling pathway - 
Rattus norvegicus (rat) 
AKT1//AKT2//CD81//IKBKG//MAPK1 
rno04010 MAPK signaling 
pathway - Rattus 
norvegicus (rat) 
AKT1//AKT2//BDNF//CACNB4//DUSP10//FAS//IKB
KG//MAP3K13//MAPK1//PLA2G4B//PTPN5//TAOK
2 
rno00140 Steroid hormone 
biosynthesis - Rattus 
norvegicus (rat) 
COMT//CYP1A1//HSD17B6//HSD3B5 
rno05217 Basal cell carcinoma - 
Rattus norvegicus (rat) 
APC2//AXIN2//CTNNB1//WNT4 
"Pathway ID" stands for Pathway identifiers used in KEGG; "Definition" stands for the definition 
of the Pathway ID; "GENES" stands for the DE genes associated with the Pathway ID. 
 
Table.2 Pathway analysis down differentially expressed gene list 
PathwayID Definition Genes 
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rno00100 Steroid biosynthesis - 
Rattus norvegicus (rat) 
CEL//DHCR7//EBP//HSD17B7//NSDHL 
rno00900 Terpenoid backbone 
biosynthesis - Rattus 
norvegicus (rat) 
ACAT3//HMGCR//HMGCS1//MVD 
rno00640 Propanoate metabolism 
- Rattus norvegicus (rat) 
ACACA//ACAT3//ACSS2//LDHAL6B 
rno00620 Pyruvate metabolism - 
Rattus norvegicus (rat) 
ACACA//ACAT3//ACSS2//LDHAL6B 
rno03320 PPAR signaling 
pathway - Rattus 
norvegicus (rat) 
ACSL3//ANGPTL4//SCD//SLC27A2//SLC27A5 
rno04640 Hematopoietic cell 
lineage - Rattus 
norvegicus (rat) 
CD5//GP5//IL1R1//IL9R//MS4A1 
rno00650 Butanoate metabolism - 
Rattus norvegicus (rat) 
ACAT3//ACSM2//HMGCS1 
rno00072 Synthesis and 
degradation of ketone 
bodies - Rattus 
norvegicus (rat) 
ACAT3//HMGCS1 
rno05416 Viral myocarditis - 
Rattus norvegicus (rat) 
MYH1//MYH2//MYH7//RT1-S3//SGCA 
rno00630 Glyoxylate and 
dicarboxylate 
metabolism - Rattus 
norvegicus (rat) 
ACAT3//ACO2 
"Pathway ID" stands for Pathway identifiers used in KEGG; "Definition" stands for the definition 
of the Pathway ID; "GENES" stands for the DE genes associated with the Pathway ID. 
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Elemene liposome and the sustained-release of its membranes 
Electrostatic spray enables good particle size distribution and morphology, as shown in Figure 4A. 
The standard curve of elemene liposome was obtained through the HPLC assay, which shows a 
linear relationship between drug release and time in the range of 5 μg/mL to 25 μg/mL. (Figure 4B). 
40% of elemene was released from elemene injection membranes within 1 h and another 46% 
released in the following 28 days. In contrast, in the elemene liposome membrane, only 28% was 
released at the first 1 h and more than 20% retained within it after 28 days. 50% of elemene was 
released from elemene injection membranes within 4 h and reached plateau in 2 days, while 
liposome membrane released 50% after 1 day and gradually reached 80% in the next (Figure 4C).  
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Figure 4. Characteristic of elemene liposome and the effect of elemene liposome membranes 
on VSMCs proliferation.  
(A) Optical image of spherical element particle. (B) The standard curve of elemene liposome. A 
linear equation is fitted to the curve. (C) Elemene has been released 40% of elemene injection 
membranes within 1 h and another 46% released in the followed 28 days. While, 28% released from 
the elemene liposome membrane at the first 1 h and more than 20% remained on it after 28 days. 
(D) The fluorescence images of cells after co-cultured for 24h. (E) This effect of elemene liposome 
membranes on VSMCs proliferation is also dose dependent. (*P<0.05 vs. no elemene treated). 
 
The liposome membrane inhibits VSMCs 
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To verify the elemene released from this liposome membranes, we have prepared three types 
elemene liposome membranes with different concentration of elemene (Figure 4D) by electrostatic 
spray. After co-cultured with VSMCs for 24h, with the increased content of elemene the cell number 
and cell spreading area on the membranes decreased and cell edge became much rougher (Figure 
4E). 
Elemene-coated stents promote endothelialization 
Elemene-coated stents was prepared by electrostatic spraying onto 316L stainless steel vascular 
stents. The coating surface was uniform as observed by scanning electron microscope and 
stereomicroscope (Figure 5A, B, C, D).    
There was no vessel perforation, laceration, aneurysm or acute thrombosis observed after 
implantation in the iliac arteries. One week after stent implantation, the surface of elemene-coated 
and the 316L stainless steel control stents showed no neointima formation. Few platelets and red 
blood cells were attached on the uncoated steel stent. 4 weeks after implantation, the surface of 
elemene coated stent has been covered with neointima completely. The cells arranged according to 
the direction of blood flow, without cell aggregation and cell adhesion. While the surface of 316L 
stainless steel stents was partially covered with neointima with some parts of the stents were 
exposed to the blood flow (data not show). 12 weeks later, the surface of elemene-coated stents and 
uncoated 316L stainless steel stents were covered by a continuous layer of neointima. There was a 
small amount of platelet and no thrombosis appeared on the neointimal surface in elemene coated 
stents. In contrast, a large number of platelet aggregation and deformation were observed for the 
surface of uncoated group (control group) (Figure 5E, F, G, H).  
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Figure 5. Elemene-coated stents and its animal experiment.  
(A, B) Stereo microscope images of elemene-coated stents prepared by electrostatic spray. (C, D) 
SEM images of elemene-coated stents prepared by electrostatic spray. (E, F) After stent 
implantation for 12 weeks, the elemene-coated stents surface was covered a layer of complete 
neointima and there are small amount of platelet adhesion and no thrombosis appears. (G, H) In the 
control group, a number of platelet adhesion and obvious aggregation and deformation were found 
on the 316L steel stents surface. 
 
Discussion  
A key cause of ISR is due to VSMCs excessive proliferation, migration to the intima and secretion 
of large amounts of extracellular matrix protein due to intimal injury. The factors that cause 
abnormal VSMCs response are multifaceted, including multiple cytokines, growth factors and 
mechanical factors caused by the environmental changes. The drugs currently used to inhibit ISR 
also suppress proliferation and migration of VSMCs 20. The most common DES that is coated with 
rapamycin and paclitaxel can effectively inhibit VSMCs proliferation and migration 21. However, 
stent thrombosis, restenosis and other side effects do occur at a later stage and have raised 
considerable concerns 22, 23.  
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A significant amount of basic research results and clinical applications have demonstrated that 
elemene is a broad-spectrum and highly effective anti-tumor drug 24, 25. Its anti-tumor mechanisms, 
such as its ability to induce apoptosis, suspend cell cycle, inhibit proliferation of endothelial cell 
and expression of vascular endothelial growth factor and inhibit tumor angiogenesis, have been 
elucidated.  
Researchers have also shown that β-elemene can inhibit neointimal hyperplasia and thrombosis, 
improving blood rheology function 12. It may also have anti-oxidative and anti-inflammatory 
properties. Wu et al have studied the effect of elemene on rat carotid artery balloon injury restenosis 
and found that it reduced neointimal area and effectively reduced ISR with no thrombosis 16. These 
research have suggested that elemene can be potentially applied to inhibit atherosclerosis and 
restenosis after PTCA.  
The experimental results of these studies suggest that inhibition of VSMCs proliferation by 
elemene is dose and time-dependent. PCNA is known to be an important factor in regulating cell 
cycle. Almost all the cells in G0~G1 phase have no obvious expression of PCNA, while the 
expressions increase significantly in G1 and reach the peak in S phase, then decrease in G2~M phase 
26. Zhao et al have shown that inhibiting the expression of PCNA in VSMCs is an ideal way to 
inhibit the proliferation of VSMCs and intimal hyperplasia 27.  
Proto-oncogenes, including c-myc, c-fos, are the initiating factors of SMC proliferation. In this 
study, it is found that c-myc has made VSMCs to get into the stage of the cell cycle and cell 
proliferation earlier. When VSMCs proliferate, c-myb overexpresses and Ca2+ increase significantly. 
It has demonstrated that the expression of PCNA and the level of intracellular Ca2+ 26 was correlated. 
The CLSM measurements have shown that elemene could increase intracellular Ca2+ firstly, and 
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then decrease back to normal level. Ca2+, an important second messenger, involved in signaling 
pathways that is closely related to cell migration 28. A variety of active peptide molecules promotes 
proliferation in a common pathway. Elemene changes free calcium in VSMCs and triggers signal 
transduction. After VSMCs are stimulated by elemene, calcium is released and the Ca2＋channels 
open, leading to the massive influx and reducing the discharge of Ca2+. All these factors cause the 
increased amount of the free Ca2+ in cells, which then lead to early apoptosis of the cells. Biological 
features of the plasma membrane changed. The Ca2+ within cells flew out quickly, leading to 
decrease in the [Ca2+] level. Ca2+ bound calmodulin to form a complex and active calmodulin kinase 
II. This triggers series of intracellular signaling chain reaction and leads to a series of cells 
pathophysiological changes such as cell migration, adhesion, and proliferation 29.  
It is speculated that inhibiting cell proliferation is related to controlling cell cycle and inducing 
apoptosis. Numerous studies 12 have found that elemene could interfere cell metabolic pathways. 
The proportion of cells increased for G0/G1 phase but decreased for S phase. Through inhibiting 
cell proliferation, elemene leads to rapid apoptosis. The study by Lu and Xiang has found that 
elemene can inhibit the activity of telomerase to cause cell apoptosis. By detecting the expression 
of apoptotic genes (caspase3, caspase7, caspase9), Chen et al have demonstrated that mRNA 
expression levels of these pro-apoptotic molecules increased significantly 30. Elemene can also 
increase the expression of P53 and such effect is dose-dependent. How elemene induces apoptosis 
and inhibits proliferation is related to P53 anomalous expression. This study shows that elemene 
change the number and morphology of VSMCs. Cells are disordered and sparse, and the spreading 
area is significantly reduced. Elemene has a dose-dependent effect on interrupting the connection 
between cells. Connexin 43 (Cx43) 31, a cardiovascular tissue connexin, participates in a variety of 
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biological activities 32, 33, such as smooth muscle cell contraction, cell growth regulation, tumor 
growth inhibition, and nerve conduction. Elemene reduces the expression of Cx43 in a dose-
dependent way.  
Other studies found that the development of ISR is clearly related to the mechanical environment 
of vessel segments after stent implantation 34, 35. With the combined effect of stent expansion and 
blood flow, vessel wall experiences pressure, tension and shear flow 36. VSMCs sensed the change 
of mechanical environment, which will then regulate the intracellular responses. Shi and Tarbell 5 
found that mechanical load could induce the change of VSMCs phenotype. Cell length increased 
significantly and the proliferation and migration are enhanced. Vascular matrix is degraded and 
VSMCs proliferation and migration caused vascular lesions 37. In vitro, culturing VSMCS under 
fluid shear stress and cyclic strain simulates the changes of mechanical environment in the blood 
vessels after stent implantation. In the selection of 4×44k gene expression profiles of IncRNA chip, 
1417 gene expressions have differences (over twice), where 699 gene expression levels went up, 
and 718 went down. About 34 gene expressions are involved the signaling pathways, including 
PPAR, MAPK, AKT and ERK1/2. MAPK is an intersection signal transmission in cells to stimulate 
VSMCs proliferation and differentiation. MAPK is mainly composed of three members: ERK, 
SAPK (also called JNK) and protein kinase P38 MARK. ERK kinase composed a number of chains 
are the most important MAPK system that can be integrated with RTK and GPCR to transfer and 
mediate multiple intracellular signaling pathways. RTK activated membrane-associated protein 
complex and catalyzed GTP to active Ras. Ras after activation enabled serine-threonine protein 
kinases prime Raf 1 and MAPK kinase (MAPKK) phosphorylation activated and MAPK to be 
further activated. MAPK activated after the cytoplasm and nucleus reactions can cause primary, 
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secondary gene responses, the regulation of cell growth, proliferation, differentiation, and other 
biological processes. Redondo reported that VSMCs proliferation requires P38 MAPK. PDGF-BB 
was adopted to activate P38 MAPK and thus stimulate cell proliferation of in vitro Wistar rat aorta 
VSMCs 38. A series of abnormal behavior of VSMCs is a result of many factors, such as abnormal 
expression of a variety of related proteins and multiple signaling pathways.  
Previous studies have demonstrated that the anti-cancer activity of elemene is mainly owing to 
its inhibition of tumor cell growth and induction of tumor cell death in vitro and in vivo. This study 
has demonstrated that the elemene has significant influence to VSMCs.  
However, despite its beneficial pharmacological effects, elemene suffers from poor water 
solubility and limited bioavailability 11. In addition, the elemene injection can cause serious venous 
irritation and phlebitis in clinical practice. Taken together, these factors limit the clinical application 
of β-elemene, therefore, a suitable formulation of the drug is required to overcome these drawbacks. 
The liposome, as a novel drug delivery system, shows significant advantages.  For example, it can 
enhance drug stability, reduce toxicity, achieve target direction action, and long-term sustained 
release. Zeng et al’s study showed that the elemene O/W microemulsion with good clarity, excellent 
stability, high entrapment efficiency 39, and improved bioavailability can be prepared successfully 
using elemene as the oil phase and drug. Shi et al have synthesized β-E-NLCs by hot melting high-
pressure homogenization method 40. The results of TEM imaging of the β-E-NLCs have revealed 
that the β-E-NLCs are spherical and the average diameter of the freshly prepared liposome is 138.9 
± 4.7 nm. The elemene liposome in our experiment is spherical with average particle size of 115.6 
± 2.1 nm.  
Electrostatic spraying is an important technology for preparing the drug-eluting stent. Different 
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elemene liposome membranes are prepared by adjusting the electrostatic spray parameters, such as 
voltage, current velocity, spray distance, and spray time. In our study, smooth and uniform coating 
to the stent surface was achieved. Besides TEM and dynamic laser light scattering, the amount of 
loading drug in the liposome and the entrapment efficiency of the liposome can be evaluated by 
high-performance liquid chromatography and gas chromatography.  
The angiography results suggest that the procedures used for stent implantation were successful. 
Although rapamycin and paclitaxel-eluting stents have an obvious effect on inhibiting restenosis, 
the inhibition of cell proliferation often delay endothelialization, which will affect endothelial 
function and cause thrombosis 41-43. Huo et al have detected the effects of elemene emulsion (β-EE) 
on rat platelet aggregation and the levels of 6-keto-prostaglandin F1 alpha (keto-PGFl α) and 
thromboxane B2 (TXB2) in plasma 44. They speculated that the inhibition of platelet aggregation 
by β-EE can result from the increased ratio of PGI2/TXA2. Our study has shown that 3 months 
after stent implantation, a layer of complete neointima formed on the elemene coated stent surface 
together with a few platelets attachment and no thrombosis was observed. However, for 316L 
stainless steel stent, a number of platelets were attached on the stent and cell aggregation were 
observed. It has been previously demonstrated that elemene-coated stents can significantly promote 
the reendothelialization of the stent implantation site. And our previous results indicate that elemene 
is effective in protecting the endothelial cells from injury induced by hydrogen peroxide in vitro 16. 
In addition, compared to the control group, elemene-coated stents has also demonstrated some 
degree of anti-thrombotic effects.  
 
Conclusions 
28 
 
In summary, this study has investigated the pharmacological characteristics of elemene on 
proliferation and apoptosis of VSMCS. In vitro results have shown that elemene has the capability 
to inhibit VSMCS proliferation in a dose-dependent and time-dependent manner, arrest cell cycle, 
interrupt cell connections, as well as induce cell differentiation and apoptosis. Although the exact 
mechanism remains to be elucidated, the findings of this study has laid solid foundation for further 
evaluation of elemene’s potential clinical application to prevent neointimal hyperplasia and 
restenosis, which are associated with oxidative stress, expansion of VSMCS and injury of surface 
endothelial coverage in vascular blood vessels.  
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Supplementary Figure S1. The diagrammatic sketch of electrostatic spray elemene lipidosome 
membranes and elemene-coated stents. 
 
